Portal de Periódicos da CAPES

Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus

2008; Wiley; Volume: 10; Issue: s2 Linguagem: Inglês

10.1111/j.1463-1326.2008.00846.x

1463-1326

D. Raccah,

Metabolism, Diabetes, and Cancer

In the early treatment of type 2 diabetes mellitus (T2DM), the addition of a basal insulin, such as insulin glargine, to existing oral therapy can help patients attain recommended glycaemic control targets, including haemoglobin A 1c (HbA 1c ) <7% and fasting blood glucose <5.5 mmol/l (<100 mg/dl). For patients close to but not at target, the management of postprandial glucose excursions with a rapid‐acting insulin, such as insulin glulisine, can provide further improvements in glycaemic control. In this review, the options for intensifying insulin therapy with the addition of one or more daily doses of prandial insulin are discussed. In addition, the advantages/disadvantages of choosing a basal–bolus vs. a premixed insulin strategy are discussed. A conceptually simple approach for the treatment of T2DM is for optimization of the basal insulin dose (added to oral antidiabetic drugs) to target fasting glycaemia followed by the addition of a single prandial dose of rapid‐acting insulin to target the largest glucose excursion. A second and third dose of prandial insulin can then be added if HbA 1c remains above target and to manage postprandial glucose excursions at other meals. Prospective studies are underway to further examine this concept and determine the benefit of this approach not only on overall glycaemic control but also on cardiovascular risk.